Nuveen Asset Management, LLC Pacira Bio Sciences, Inc. Transaction History

Nuveen Asset Management, LLC

$340 Billion
Q4 2024

A detailed history of Nuveen Asset Management, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 625,917 shares of PCRX stock, worth $13.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

625,917

Previous 298,163 109.92%

Holding current value

$13.3 Million

Previous $4.49 Million 162.63%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$15.3 - $20.33 $5.01 Million - $6.66 Million	327,754 Added 109.92%	625,917 $11.8 Million
Q3 2024 Nov 14, 2024	SELL	$11.7 - $28.46 $4.83 Million - $11.8 Million	-413,085 Reduced 58.08%	298,163 $4.49 Million
Q2 2024 Aug 09, 2024	BUY	$25.5 - $31.51 $3.69 Million - $4.55 Million	144,535 Added 25.5%	711,248 $20.3 Million
Q1 2024 May 13, 2024	BUY	$27.7 - $35.48 $10.7 Million - $13.7 Million	386,538 Added 214.53%	566,713 $16.6 Million
Q4 2023 Feb 14, 2024	BUY	$26.32 - $34.31 $1.58 Million - $2.06 Million	59,998 Added 49.92%	180,175 $6.08 Million
Q3 2023 Nov 14, 2023	SELL	$30.68 - $40.09 $28,961 - $37,844	-944 Reduced 0.78%	120,177 $3.69 Million
Q2 2023 Aug 14, 2023	BUY	$36.12 - $47.5 $71,698 - $94,287	1,985 Added 1.67%	121,121 $4.85 Million
Q1 2023 May 15, 2023	SELL	$35.53 - $43.38 $1.7 Million - $2.08 Million	-47,844 Reduced 28.65%	119,136 $4.86 Million
Q4 2022 Feb 14, 2023	SELL	$38.19 - $57.45 $8.72 Million - $13.1 Million	-228,370 Reduced 57.76%	166,980 $6.45 Million
Q3 2022 Nov 14, 2022	SELL	$51.24 - $58.89 $153,207 - $176,081	-2,990 Reduced 0.75%	395,350 $21 Million
Q2 2022 Aug 15, 2022	SELL	$51.49 - $81.64 $687,185 - $1.09 Million	-13,346 Reduced 3.24%	398,340 $23.2 Million
Q1 2022 May 16, 2022	SELL	$60.03 - $76.49 $253,146 - $322,558	-4,217 Reduced 1.01%	411,686 $29.9 Million
Q4 2021 Feb 14, 2022	BUY	$47.97 - $62.21 $2.37 Million - $3.08 Million	49,461 Added 13.5%	415,903 $25 Million
Q3 2021 Nov 12, 2021	BUY	$54.64 - $61.3 $309,426 - $347,141	5,663 Added 1.57%	366,442 $20.5 Million
Q2 2021 Aug 16, 2021	BUY	$59.18 - $69.99 $6.04 Million - $7.15 Million	102,102 Added 39.47%	360,779 $21.9 Million
Q1 2021 May 17, 2021	SELL	$59.31 - $78.82 $1.11 Million - $1.48 Million	-18,717 Reduced 6.75%	258,677 $18.1 Million
Q4 2020 May 17, 2021	BUY	$50.47 - $66.26 $4.04 Million - $5.3 Million	79,979 Added 40.51%	277,394 $16.6 Million
Q4 2020 Feb 16, 2021	SELL	$50.47 - $66.26 $2.06 Million - $2.7 Million	-40,775 Reduced 17.12%	197,415 $11.8 Million
Q3 2020 Nov 16, 2020	SELL	$51.97 - $63.0 $488,933 - $592,704	-9,408 Reduced 3.8%	238,190 $14.3 Million
Q2 2020 Aug 14, 2020	SELL	$30.8 - $52.47 $4.6 Million - $7.84 Million	-149,327 Reduced 37.62%	247,598 $13 Million
Q1 2020 May 14, 2020	SELL	$28.4 - $50.7 $2.56 Million - $4.57 Million	-90,101 Reduced 18.5%	396,925 $13.3 Million
Q4 2019 Feb 14, 2020	SELL	$36.31 - $46.83 $14.4 Million - $18.6 Million	-396,598 Reduced 44.88%	487,026 $22.1 Million
Q3 2019 Nov 14, 2019	BUY	$35.66 - $44.99 $449,209 - $566,739	12,597 Added 1.45%	883,624 $33.6 Million
Q2 2019 Aug 15, 2019	BUY	$36.57 - $47.97 $31.9 Million - $41.8 Million	871,027 New	871,027 $37.9 Million
Q1 2018 May 14, 2018	SELL	$29.98 - $46.35 $1.33 Million - $2.06 Million	-44,438 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$31.85 - $46.95 $163,963 - $241,698	5,148 Added 13.1%	44,438 $0
Q3 2017 Nov 14, 2017	BUY	$35.7 - $39.5 $1.4 Million - $1.55 Million	39,290	39,290 $1.48 Million

Others Institutions Holding PCRX

# of Institutions

259

Shares Held

51M

Call Options Held

289K

Put Options Held

130K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $975M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Pacira Bio Sciences, Inc. Transaction History